The authors found that patients on GLP-1RAs had a significantly lower risk of developing pancreatic cancer compared to those on insulin (hazard ratio [HR]: 0.56), DPP-4 inhibitors (HR: 0.80), SGLT2 inhibitors (HR: 0.78), and sulfonylureas (HR: 0.84)
However, the cost and utilization of these powerful drugs require careful planning
Ill be back again and again and again
Theres a good chance that, as we have more patients who get GLP-1 agonists for obesity, we might find similar results, Thosani says
They ate better foods
Watch for fatigue, irritability, or trouble concentrating, as these are early signs that your food intake may not be meeting your body's needs